Computational Modeling To Adapt Neutralizing Antibody
- Sandia National Lab. (SNL-NM), Albuquerque, NM (United States)
Monoclonal antibodies (mAbs) is the leading therapy for viral infections because it provides immediate protection and can be administered at higher levels than in a natural immune response. Finding mAbs that neutralize a broad spectrum of viral targets has proven difficult because many species and strains exist and blanket targeting is a slow and laborious process to experimentally screen 108 variants. A new method is needed to rapidly redesign mAbs for homologous targets. This project speeds up redesign using structure-based computational design to reduce the mAbs search space to a manageable level and screen mutants at a much higher rate than in experiments. Computation will also provide critical knowledge about the fundamental interactions. The project will adapt S230, a human antibody that neutralizes SARS-CoV, to neutralize SARS-COV-2.
- Research Organization:
- Sandia National Laboratories (SNL-NM), Albuquerque, NM (United States)
- Sponsoring Organization:
- USDOE National Nuclear Security Administration (NNSA)
- DOE Contract Number:
- AC04-94AL85000; NA0003525
- OSTI ID:
- 1673826
- Report Number(s):
- SAND--2020-10755; 691421
- Country of Publication:
- United States
- Language:
- English
Similar Records
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
Journal Article
·
Thu Oct 28 20:00:00 EDT 2021
· Nature Immunology
·
OSTI ID:1837258